Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
C3.ai is now available to purchase on the New York Stock Exchange. Here’s how you can buy in.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $22.54 |
|---|---|
| 52-week range | $22.56 - $176.94 |
| 50-day moving average | $34.60 |
| 200-day moving average | $49.36 |
| Wall St. target price | $55.44 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.54 from 2022-01-27
| 1 week (2022-01-21) | -11.43% |
|---|---|
| 1 month (2021-12-28) | -30.41% |
| 3 months (2021-10-28) | -49.50% |
| 6 months (2021-07-28) | -61.47% |
| 1 year (2021-01-28) | -84.77% |
|---|---|
| 2 years (2020-01-24) | N/A |
| 3 years (2019-01-24) | N/A |
| 5 years (2017-01-24) | N/A |
| Revenue TTM | $212.1 million |
|---|---|
| Gross profit TTM | $138.7 million |
| Return on assets TTM | -11.07% |
| Return on equity TTM | -21.43% |
| Profit margin | -63.71% |
| Book value | $9.79 |
| Market capitalisation | $2.7 billion |
TTM: trailing 12 months
We're not expecting C3-ai to pay a dividend over the next 12 months.
You may also wish to consider:
C3. ai, Inc. operates as an enterprise artificial intelligence (AI) software company in North America, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It offers software-as-a-service applications for enterprises. Its software solutions include C3 AI Suite, a platform-as-a-service application development and runtime environment that enables customers to design, develop, and deploy enterprise AI applications; C3 AI Ex Machina to analysis-ready data; and C3 AI CRM, an AI-first customer relationship management solution to drive customer-facing operations. It also offers C3 AI applications, including C3 AI Inventory Optimization, a solution to optimize raw material, in-process, and finished goods inventory levels; C3 AI Supply Network Risk, which provides visibility into risks of disruption throughout the supply chain operations; C3 AI Customer Churn Management, which enables account executives and relationship managers to monitor customer satisfaction, as well as to prevent customer churn with AI-based and human-interpretable predictions and warning; C3 AI Production Schedule Optimization, a solution for scheduling production; C3 AI Predictive Maintenance, which provides insight into asset risk to maintenance planners and equipment operators; C3 AI Fraud Detection solution that identify revenue leakage or maintenance and safety; and C3 AI Energy Management solution. In addition, it offers integrated turnkey enterprise AI applications for oil and gas, chemicals, utilities, manufacturing, financial services, defense, intelligence, aerospace, healthcare, and telecommunications market segments.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.